1 / 52

Endometriosis

Endometriosis. The Disease Definitions and Epidemiology Aetiology Symptomatology. Diagnosis Laparoscopy Laparoscopic Images The Outlook. Endometriosis (continued). Treatment Current Treatment Options Non-specific Therapies Specific Therapies Progestins Danazol GnRH Agonists

bruno
Télécharger la présentation

Endometriosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Endometriosis • The Disease • Definitions and Epidemiology • Aetiology • Symptomatology • Diagnosis • Laparoscopy • Laparoscopic Images • The Outlook

  2. Endometriosis (continued) • Treatment • Current Treatment Options • Non-specific Therapies • Specific Therapies • Progestins • Danazol • GnRH Agonists • Surgery • Guidelines • Summary

  3. Endometriosis: The Disease Definitions and Epidemiology

  4. Definitions • ‘The presence of endometrial-like tissue outside the uterus… induces a chronic, inflammatory reaction’1 • Endometriosis: derived from ancient Greek:endo - ‘inside’ and metra - ‘womb’ • ‘…found predominantly in women of reproductive age, from all ethnic and social groups’1 • ‘…associated symptoms can impact on general physical, mental and social well-being’1 • Kennedy S, Berggvist A, Chapron C et al. Hum Reprod 2005.

  5. Epidemiology • Endometriosis is a prevalent condition: • 5–10% of the female population1,2 • ~5.5 million women in USA; ~16 million in Europe3 • Affects women during reproductive years • Younger age at onset predicts more severe disease4 • ~50% in women with dysmenorrhea; 75% in women with pelvic pain; 25–40% in infertile/subfertile women5,6 • Mounsey AL et al. Am Fam Phys 2006; • Eskenazi B & Warner ML. Obstet Gynecol Clin North Am 1997; • Taylor MM AORN 2003; • Ballweg ML et al. J Pediatr Adolesc Gynecol 2003; • Child TJ et al. Drugs 2001; • Cramer DW et al. Ann N Y Acad Sci 2002.

  6. Endometriosis: The Disease Aetiology

  7. Sites Commonly Affected • ‘Extent of disease varies from a few, small lesions on otherwise normal pelvic organs to large, ovarian endometriotic cysts (endometriomas),and/or extensive fibrosis and adhesion formation causing markeddistortion of pelvic anatomy’1 • Pelvic cavity: • Peritoneum, ovaries,pouch of Douglas,uterosacral ligaments • Other sites: • Vagina, bowel, bladder, ureters • Rare sites: • Lungs, brain • Kennedy S, Berggvist A, Chapron C et al. Hum Reprod 2005.

  8. Critical Aspects of Pathogenesis • Endometrial-like cells attach to peritoneal tissue/other sites • Cellular infiltration/invasion, involving angiogenesis • Cellular proliferation • Inflammation which can cause • Nerve irritation • Adhesions • Individual variation Mahutte NG, Kayisli U, Arici A. Endometriosis in Clinical Practice. 2005; Fraser IS. J Hum Reprod Sci 2008.

  9. Risk Factors • Pathophysiology unclear • Certain characteristics lead to increased/decreased risk • Mounsey AL et al. Am Fam Phys 2006; • Missmer SA et al. Obstet Gynecol 2004; • Bischoff F et al. Ann N Y Acad Sci 2004; • Eskenazi B et al. Obstet Gynecol Clin North Am 1997; • Cramer DW et al. Ann N Y Acad Sci 2002; • Hediger ML et al. Fertil Steril 2005.

  10. Endometriosis: The Disease Symptomatology

  11. Symptomatology • Typical symptoms: • Dysmenorrhea • Premenstrual pain • Dyspareunia • Diffuse/chronic pelvic pain • Other symptoms: • Perimenstrual symptoms(e.g. bowel- or bladder-associated) • Back pain • Chronic fatigue • Significant proportion of cases asymptomatic • Diagnosis based on symptoms alone can be difficult • Variable presentation • Similar to other conditions – irritable bowel syndrome,pelvic inflammatory disease Sinaii N, Plumb K, Cotton L et al. Fertil Steril 2008.

  12. Prevalence and Overlap of Symptoms Pelvic pain + dysmenorrhea 25.2% Dysmenorrhea only 12.7% Pelvic pain only 6.5% Dyspareunia + pelvic pain + dysmenorrhea 34.4% Dysmenorrhea + dyspareunia 6.5% Pelvic pain + dyspareunia 3.3% Dyspareunia only 0.7% Sinaii N, Plumb K, Cotton L et al. Fertil Steril 2008. 10.7% of women did not report any gynecologic pain symptoms.

  13. Infertility • Endometriosis is frequently associated with infertility • 30–40% experience subfertility or infertility • Lesions cause chronic inflammation/adhesions, impacting fertility • Infertility may be the sole presenting symptom • 25–40% of infertile women have endometriosis • Endometriosis may be diagnosed by chance by an infertility specialist Ozkan S, Murk W, Arici A. Ann NY Acad Sci 2008.

  14. Natural History of Disease • Highly variable and difficult to predict in individual women • Progressive course characterised by worsening of pain1 • Younger onset age predicts more severe disease course2 • Spontaneous regression is possible3 • Koninckx PR, Meuleman C, Demeyere S et al. Fertil Steril 1991; • Ballweg J Pediatr Adolesc Gynecol 2003; • Mahmood TA, Templeton A. Hum Reprod 1990.

  15. What is the Impact of Endometriosis? Morbidity Absenteeism Socio-economic cost Quality of life Educational opportunities Daily function Self-esteem Fertility Mounsey AL, Wilgus A, Slawson DC. Am Fam Phys 2006; Gao X, Yeh YC, Outley J et al. Curr Med Res Opin 2006.

  16. Endometriosis: Diagnosis

  17. Diagnosis Diagnosis often delayed (average 8.3 years1) Typical clinical symptoms and signs(e.g. uterosacral nodularity)2,3 Suggestive Laparoscopic visualisation – ideally with confirmatory histology1 Magnetic resonance imaging and ultrasound4 Laboratory tests currently fail to show predictive value5,6 New semi-quantitative procedures being assessed7 Definitive New techniques • Kennedy S, Bergqvist A, Chapron C, et al. Hum Reprod 2005; • Mounsey AL, Wilgus A, Slawson DC. Am Fam Phys 2006; • Matorras R, Rodríguez F, Pijoan JI, et al. Am J Obstet Gynecol 1996; • Bazot et al. J Minim Invasive Gynecol 2005; • Bedawy et al. Clin Chem Acta 2004; • Matalliotakis et al. Arch Gynecol Obstet 2005; • Fraser et al. J Hum Reprod Sci 2008.

  18. Diagnostic Pathway Clinical presentation: typical symptoms Endometriosis suspected History Examination Investigations Consider differential diagnoses Likely diagnosis of endometriosis –management considerations

  19. Typical Symptoms • Dysmenorrhea • Most commonly reported symptom • Severe form highly suggestive of endometriosis1 • Dyspareunia • Commonly found in peritoneal (88%) and rectovaginal (100%) disease2 • No relationship between stage and site of disease • Normal clinical examination cannot exclude endometriosis3–5 • Mahmood TA, Templeton A. Hum Reprod 1991; • Gruppo Italiano per lo Studio dell’Endometriosis. Hum Reprod 2001. 3. Koninckx PR, Meuleman C, Oosterlynck D et al. Fertil Steril 1996; 4. Chapron C, Dubuisson JB, Pansini V et al. Fertil Steril 2002; 5. Eskenazi B, Warner M, Bonsignore L et al. Fertil Steril 2001.

  20. Endometriosis: Diagnosis Laparoscopy

  21. Laparoscopy: Advantages and disadvantages • Kennedy S, Bergqvist A, Chapron C et al. Hum Reprod 2005; • Brosens IA, Brosens JJ. Eur J Obstet Gynecol Reprod Biol 2000; • Al-Jefout M, Dezarnaulds G, Cooper M et al. Hum Reprod 2009.

  22. Laparoscopic Technique

  23. Laparoscopic Technique

  24. Laparoscopic Findings • Lesions1 • ‘Powderburn’/‘gunshot’ lesions on ovaries, serosal surfaces, peritoneum • Black, dark-brown or bluish puckered lesions, nodules or small cystscontaining old hemorrhage surrounded by variable extent of fibrosis • Atypical or ‘subtle’ lesions – implants (petechial, vesicular, polypoid, hemorrhagic, red flame-like), serous/clear vesicles • White plaques/scarring, yellow-brown discoloration of peritoneum • Endometriomas (‘chocolate cysts’)1 • Contain thick tar-like fluid • Deeply infiltrating endometriotic nodules1 • Extend >5 mm beneath peritoneum • May involve uterosacral ligaments, vagina, bowel, bladder or ureters • Depth of infiltration related to type and severity of symptoms • Kennedy S, Berggvist A, Chapron C et al. Hum Reprod. 2005.

  25. Laparoscopic Disease Classification (rASRM Score) rASRM, revised American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine. Fertil Steril 1997.

  26. Laparoscopic Disease Classification (rASRM Score) • Lesion assessment based on points system at laparoscopy1 • Classification may help determine risk of infertility • No correlation between classification and symptoms2 • Revised American Society for Reproductive Medicine. Fertil Steril 1997; • Kennedy S, Berggvist A, Chapron C et al. Hum Reprod 2005.

  27. Endometriosis: Diagnosis Laparoscopic Images

  28. Laparoscopic Images

  29. Laparoscopic Images

  30. Laparoscopic Images

  31. Endometriosis: Diagnosis The Outlook

  32. Diagnosis Non-invasive techniques remain under investigation Detection of nerve fibres in endometrial biopsy1 Biopsy Laboratory tests(e.g. serum cancer antigens CA 125, CA 19-9, serumIL-6, peritoneal fluid TNFα), fail to showpredictive value4,5 Ultrasound, computerised tomography scan or magnetic resonance imaging – may be useful adjunctive investigations2,3 Transvaginal ultrasound can detect e.g. endometriomas (but not lesions)1 Lab-based tests Imaging • Kennedy S, Bergqvist A, Chapron C, et al. Hum Reprod 2005; • Mounsey AL, Wilgus A, Slawson DC. Am Fam Phys 2006; • Matorras R, Rodríguez F, Pijoan JI, et al. Am J Obstet Gynecol 1996; • Bazot et al. J Minim Invasive Gynecol 2005; • Bedawy et al. Clin Chem Acta 2004; • Matalliotakis et al. Arch Gynecol Obstet 2005; • Fraser et al. J Hum Reprod Sci 2008.

  33. Endometriosis: Treatment Current Treatment Options

  34. Overview • No permanent cure for endometriosis • Aims of treatment (patient-dependent): • Alleviate pain and other symptoms • Reduce lesions • Maintain/restore fertility • Avoid recurrence • Improve quality of life

  35. Individualisation of Therapy • No single approach ideal for all patients • Tailor therapy to needs and choices of patient1 • Objective of individualised therapy: • Manage complaint (pain/infertility) • Optimise balance of efficacy, safety and tolerability profiles • Enhance adherence • Kennedy S, Berggvist A, Chapron C et al. Hum Reprod 2005.

  36. Surgical Therapy • Aimed at removing endometrial implants and restoring fertility • Efficacy reflects the skill of the surgeon • Recurrence is common: 40–50% at 5 years1,2 • Mounsey AL, Wilgus A, Slawson DC. Am Fam Phys 2006; • Guo SW. Hum Reprod Update 2009.

  37. Medical Therapy Non-specific therapies –not approved in endometriosis Including non-steroidalanti-inflammatory drugs and combined oral contraceptives Specific therapies –approved in endometriosis e.g. gonadotropin-releasinghormone agonists, danazol and some progestins

  38. Treatment Approach • ‘Endometriosis should be viewed as a chronic disease that requires a life-long management plan with the goal of maximising the use of medical treatment andavoiding repeated surgical procedures’ Practice Committee of the American Society for Reproductive Medicine. Fertil Steril 2008.

  39. NSAIDs • General, non-specific pain relief • Controlled trial data lacking1,2 • No single NSAID shows superior efficacy1 • Potential adverse effects in gastrointestinal tract1,2 NSAID, non-steroidal anti-inflammatory drug. • Allen C, Hopewell S, Prentice A. Cochrane Database Syst Rev 2005; • Kennedy S et al. Hum Reprod 2005.

  40. Combined Oral Contraceptives • Combined oral contraceptives are widely used off-label for endometriosis • Lack of randomised controlled trials1,2 • Limited guidance on optimal regimens • Estrogen in oral contraceptives appears counter-productive for endometriosis treatment2 • Hormonal therapies indicated for endometriosis counteract estrogen effects on endometrial tissue • Estrogenic adverse effects (nausea, weight gain, water retention, increased thromboembolic risk)1 • Davis LJ, Kennedy SS, Moore J et al. Cochrane Database Syst Rev 2007; • Crosignani P, Olive D, Bergqvist A et al. Hum Reprod Update 2006.

  41. Endometriosis: Medical therapy Specific Therapies

  42. Hormonal Therapy* GnRH agonists (suppression of FSH/LH via desensitisation and down-regulation of pituitary GnRH receptors) • Leuprolin • Goserelin • Buserelin • Triptorelin • Nafarelin • Avorelin Progestins / antiprogestin (suppression of FSH/LH, some have additional properties, e.g. anti-inflammatoric) • MPA (oral/im/sc) • Dydrogesterone • Norethisterone • Dienogest • Gestrinone Androgens (suppression of FSH/LH, anti-estrogenic and hyperandrogenism) • Danazol * Not all products are available in all countries. FSH, follicle stimulating hormone; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; MPA, medroxyprogesterone acetate Vercellini et al. Best Pract Res Clin Obstet Gynaecol 2008; Mihalyi et al. Expert Opin Emerg Drugs 2006.

  43. Endometriosis treatment: Progestins

  44. Progestins • Synthetic hormones with progesterone-like activity1,2 • First used to treat endometriosis in the 1950s3, most have not been developed for the treatment of endometriosis • Derived from different steroids (e.g. progesterone, testosterone),differ in their actions • Limited evidence from controlled (especially placebo-controlled) trials, scarcity of data also hampers the selection of one progestin over another • Adverse events include irregular bleeding and (especially with older agents) weight gain, headaches, acne and adverse lipid changes4,5 • Newer types selectively bind progesterone receptors specifically to minimise androgenic, estrogenic or glucocorticoid side-effects1 • Sitruk-Ware R. Hum Reprod Update 2006; • Schindler AE et al. Maturitas 2003; • Kistner RW. Am J Obstet Gynecol 1958; • Winkel CA & Scialli AR. J Womens Health Gend Based Med 2002; • Vercellini P et al. Hum Reprod Update 2003.

  45. Endometriosis treatment: GnRH Agonists

  46. GnRH Agonists • Synthetic peptides modelled on hypothalamic GnRH • Mechanism of action: down-regulation of pituitary gonadotropin secretion, inducing a hypoestrogenic anovulatory state1,2 • Considered ‘standard’ treatment for endometriosis due to high efficacy1–4 • Hypoestrogenic side-effects, including BMD decrease • Limited to short-term use (6 months) in absence of ‘add-back’ therapy • ‘Add-back’ therapy adds to expense; optimal regimens not established • Caution in younger women not reached maximum BMD GnRH, gonadotropin-releasing hormone; BMD, bone mineral density. • Winkel CA et al. J Women’s Health Gender-Based Med 2001; • Sinaii N et al. Fertil Steril 2007; • Crosignani P et al. Hum Reprod Update 2006; • Mounsey AL et al. Am Fam Phys 2006.

  47. Endometriosis: Surgical therapy Surgery

  48. Surgical Treatment • Usually performed as laparoscopy in one procedure combining diagnosis and treatment • Surgical intervention includes: excision or ablation of endometriotic lesions, removal of endometriotic cysts, adhesiolysis1 • Frequently combined with follow up medical therapy • Preferred approach in infertile patients2 • Role in pain relief unclear2 • Success reflects the skill of practitioner • Recurrence of endometriosis is common –5-year recurrence rate approximately 40–50%3 • Mounsey AL, Wilgus A, Slawson DC. Am Fam Phys 2006; • Jacobson TZ et al. Cochrane Database 2008; • Guo SW. Hum Reprod Update 2009.

  49. Laparoscopic Technique

  50. Endometriosis: Summary

More Related